Exscientia

Showing 11 posts of 11 posts found.

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023
Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …

laboratory-testing-az

Exscientia to collaborate with EQRx on drug development

June 25, 2021
Medical Communications AI, Exscientia, clinical drug development

Exscientia and EQRx have announced a strategic research and development collaboration agreement aiming to substantially accelerate the delivery of novel …

Exscientia launch trial of third AI-designed molecule

May 13, 2021
AI, Altzeimer's, Exscientia

Exscientia has launched Phase I trials in the US of DSP-0038 for the treatment of Alzheimer’s disease psychosis, the third …

Exscientia enter first-ever AI cancer drug into Phase I trials

April 9, 2021
Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news

Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …

david_nicholson

Allergan R&D Chief named as Chairman of Exscientia’s Board of Directors

October 8, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Exscientia, appointment

Artificial intelligence-driven drug discovery firm Exscientia has named industry veteran Dr David Nicholson, current Executive Vice President and Chief R&D …

david_hallett

AI firm Exscientia appoints COO and Head of Drug Discovery

January 31, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Exscientia, appointment

AI drug discovery firm Exscientia has announced the appointment of Dr David Hallett as its Chief Operating Officer and Head …

1201709115_133b3927a3_b

Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

January 10, 2020
Medical Communications Bayer, Exscientia, oncology

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. …

celgene_1_02

Celgene inks drug discovery deal worth at least £25m with AI firm Exscientia

March 21, 2019
Research and Development Celgene, Exscientia, drug discovery, pharma

Celgene has entered into a new three-year partnership with British artificial intelligence and drug discovery firm Exscientia to the value …

ai_graphic

The future is now: The transformative power of AI

February 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Exscientia, GSK, GlaxoSmithKline, artificial intelligence, drug development, pharma

With the technologies reaching exciting levels of maturity and adoption, Matt Fellows investigates how AI and machine learning can be …

Exscientia appoints Oxford Innovation Sciences founder and ex-Lansdowne CEO as Deputy Chairman

December 11, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Snow, Exscientia, appointment

Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its …

gsk_boronia_australia

GSK signs $43 million AI-based drug discovery deal with Exscientia

July 3, 2017
Research and Development, Sales and Marketing AstraZeneca, Exscientia, GSK

With AI partnerships becoming increasingly common in the life sciences industry, it has emerged that GSK is to partner up …

Latest content